author-photo

Afshin Salsali

Boehringer Ingelheim

70

Papers

3049

Citations

Citation Trend

Filter By

Papers (50) Sort By

Journal Conference Others

Author response for "Potential contribution of haemoconcentration to changes in lipid parameters with empagliflozin in patients with type 2 diabetes mellitus – a post hoc analysis of pooled data from four phase III randomized clinical trials"

2021 Diabetes, Obesity and Metabolism
Show All
- Source
- Cite
- Save
Citations (0)
Review for "Dapagliflozin effects on lung fluid volumes in patients with heart failure and reduced ejection fraction: results from the DEFINE‐HF Trial"

2021 Diabetes, Obesity and Metabolism
- Afshin Salsali
Show All
- Source
- Cite
- Save
Citations (0)
SGLT2 inhibition in patients hospitalized for acute decompensated heart failure: rationale for and design of the EMPULSE trial

2021 European Journal of Heart Failure
Show All
- Source
- Cite
- Save
Citations (9)
Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA-REG OUTCOME trial.

2021 Esc Heart Failure
Show All
- Source
- Cite
- Save
Citations (0)
Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes.

2020 European Heart Journal
Show All
- Source
- Cite
- Save
Citations (24)
Review for "Long‐Term Efficacy and Safety of Dapagliflozin in Patients with Inadequately Controlled Type 1 Diabetes: Pooled 52‐Week Outcomes from the DEPICT‐1 and ‐2 Studies"

2020 Diabetes, Obesity and Metabolism
- Afshin Salsali
Show All
- Source
- Cite
- Save
Citations (0)
Review for "Efficacy and safety of dapagliflozin plus saxagliptin versus insulin glargine over 52 weeks as add‐on to metformin with or without sulfonylurea in patients with type 2 diabetes: A randomized, parallel‐design, open‐label, phase 3 trial"

2020 Diabetes, Obesity and Metabolism
- Afshin Salsali
Show All
- Source
- Cite
- Save
Citations (0)
Review for "Efficacy and safety of Exenatide as add‐on therapy for type 2 diabetes patients with intensive insulin regimen: a randomized double‐blind trial"

2020 Diabetes, Obesity and Metabolism
- Afshin Salsali
Show All
- Source
- Cite
- Save
Citations (0)
Kidney Function After Initiation And Discontinuation Of Empagliflozin (EMPA) In Heart Failure (HF) Patients (Pts) With And Without Type 2 Diabetes (T2D): Insights From The Emperial Trials

2020 Journal of Cardiac Failure
Show All
- Source
- Cite
- Save
Citations (0)
Antihyperglycemic and Blood Pressure Effects of Empagliflozin in Black Patients With Type 2 Diabetes Mellitus and Hypertension

2019 Circulation
Show All
- Source
- Cite
- Save
Citations (0)